SIRT2 inhibition exacerbates neuroinflammation and blood-brain barrier disruption in experimental traumatic brain injury by enhancing NF-κB p65 acetylation and activation

Journal of Neurochemistry

Volumn 136, Issue 3, 2016, Pages 581-593

  Yuan, Fang ^a   Xu, Zhi Ming ^a   Lu, Li Yan ^b   Nie, Hui ^a   Ding, Jun ^a   Ying, Wei Hai ^a   Tian, Heng Li ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

blood brain barrier; cerebral edema; inflammation; SIRT2; traumatic brain injury

Indexed keywords

AQUAPORIN 4; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; SIRTUIN 2; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUTROPHIL COLLAGENASE; PROTEIN ZO1; RELA PROTEIN, MOUSE; SMALL INTERFERING RNA; TJP1 PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN WATER; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE EXACERBATION; DISEASE SEVERITY; EXPERIMENTAL BRAIN INJURY; MACROPHAGE ACTIVATION; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; UPREGULATION; ACETYLATION; ANIMAL; BRAIN INJURY; C57BL MOUSE; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; ENCEPHALITIS; GENETICS; METABOLISM; PATHOLOGY; TIME FACTOR;

ACETYLATION; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; BRAIN INJURIES; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALITIS; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MATRIX METALLOPROTEINASE 8; MICE; MICE, INBRED C57BL; RNA, SMALL INTERFERING; SIRTUIN 2; TIME FACTORS; TRANSCRIPTION FACTOR RELA; UP-REGULATION; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84955389681     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13423     Document Type: Article

References (40)

1. Bobrowska A., Donmez G., Weiss A., Guarente L., and, Bates G., (2012) SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo. PLoS ONE 7, e34805.
2. Chen L. F., Williams S. A., Mu Y., Nakano H., Duerr J. M., Buckbinder L., and, Greene W. C., (2005) NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol. Cell. Biol. 25, 7966-7975.
3. Chen H., Wu D., Ding X., and, Ying W., (2015a) SIRT2 is required for lipopolysaccharide-induced activation of BV2 microglia. NeuroReport 26, 88-93.
4. Chen X., Wales P., Quinti L., et al,. (2015b) The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia. PLoS ONE 10, e0116919.
5. Choi Y. H., Kim H., Lee S. H., Jin Y. H., and, Lee K. Y., (2013) ERK1/2 regulates SIRT2 deacetylase activity. Biochem. Biophys. Res. Commun. 437, 245-249.
6. Chopra V., Quinti L., Kim J., et al,. (2012) The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep. 2, 1492-1497.
7. Di Fruscia P., Zacharioudakis E., Liu C., et al,. (2015) The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model. ChemMedChem 10, 69-82.
8. Donkin J. J., and, Vink R., (2010) Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. Curr. Opin. Neurol. 23, 293-299.
9. Donmez G., Arun A., Chung C. Y., McLean P. J., Lindquist S., and, Guarente L., (2012) SIRT1 protects against alpha-synuclein aggregation by activating molecular chaperones. J. Neurosci. 32, 124-132.
10. Eskandarian H. A., Impens F., Nahori M. A., Soubigou G., Coppee J. Y., Cossart P., and, Hamon M. A., (2013) A role for SIRT2-dependent histone H3K18 deacetylation in bacterial infection. Science 341, 1238858.
11. Grall F., Gu X., Tan L., et al,. (2003) Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor alpha in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kappaB-mediated induction of the Ets transcription factor ESE-1. Arthritis Rheum. 48, 1249-1260.
12. Hoffmann G., Breitenbucher F., Schuler M., and, Ehrenhofer-Murray A. E., (2014) A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J. Biol. Chem. 289, 5208-5216.
13. Houtkooper R. H., Pirinen E., and, Auwerx J., (2012) Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 13, 225-238.
14. Kim D., Nguyen M. D., Dobbin M. M., et al,. (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169-3179.
15. Kim M. J., Kim D. W., Park J. H., et al,. (2013) PEP-1-SIRT2 inhibits inflammatory response and oxidative stress-induced cell death via expression of antioxidant enzymes in murine macrophages. Free Radic. Biol. Med. 63, 432-445.
16. Laird M. D., Sukumari-Ramesh S., Swift A. E., Meiler S. E., Vender J. R., and, Dhandapani K. M., (2010) Curcumin attenuates cerebral edema following traumatic brain injury in mice: a possible role for aquaporin-4? J. Neurochem. 113, 637-648.
17. Lee A. S., Jung Y. J., Kim D., Nguyen-Thanh T., Kang K. P., Lee S., Park S. K., and, Kim W., (2014) SIRT2 ameliorates lipopolysaccharide-induced inflammation in macrophages. Biochem. Biophys. Res. Commun. 450, 1363-1369.
18. Li Y., Nie H., Wu D., Zhang J., Wei X., and, Ying W., (2013) Poly(ADP-ribose) polymerase mediates both cell death and ATP decreases in SIRT2 inhibitor AGK2-treated microglial BV2 cells. Neurosci. Lett. 544, 36-40.
19. Lin J., Sun B., Jiang C., Hong H., and, Zheng Y., (2013) Sirt2 suppresses inflammatory responses in collagen-induced arthritis. Biochem. Biophys. Res. Commun. 441, 897-903.
20. Lo Sasso G., Menzies K. J., Mottis A., Piersigilli A., Perino A., Yamamoto H., Schoonjans K., and, Auwerx J., (2014) SIRT2 deficiency modulates macrophage polarization and susceptibility to experimental colitis. PLoS ONE 9, e103573.
21. Loane D. J., Pocivavsek A., Moussa C. E., Thompson R., Matsuoka Y., Faden A. I., Rebeck G. W., and, Burns M. P., (2009) Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury. Nat. Med. 15, 377-379.
22. Luthi-Carter R., Taylor D. M., Pallos J., et al,. (2010) SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl Acad. Sci. USA 107, 7927-7932.
23. Mannix R. C., and, Whalen M. J., (2012) Traumatic brain injury, microglia, and Beta amyloid. Int. J. Alzheimers Dis. 2012, 608732.
24. Masel B. E., and, DeWitt D. S., (2010) Traumatic brain injury: a disease process, not an event. J. Neurotrauma 27, 1529-1540.
25. Maxwell M. M., Tomkinson E. M., Nobles J., Wizeman J. W., Amore A. M., Quinti L., Chopra V., Hersch S. M., and, Kazantsev A. G., (2011) The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum. Mol. Genet. 20, 3986-3996.
26. Nie H., Hong Y., Lu X., Zhang J., Chen H., Li Y., Ma Y., and, Ying W., (2014) SIRT2 mediates oxidative stress-induced apoptosis of differentiated PC12 cells. NeuroReport, 25, 838-842.
27. de Oliveira R. M., Sarkander J., Kazantsev A. G., and, Outeiro T. F., (2012) SIRT2 as a therapeutic target for age-related disorders. Front. Pharmacol. 3, 82.
28. Outeiro T. F., Kontopoulos E., Altmann S. M., et al,. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516-519.
29. Pais T. F., Szego E. M., Marques O., Miller-Fleming L., Antas P., Guerreiro P., de Oliveira R. M., Kasapoglu B., and, Outeiro T. F., (2013) The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. EMBO J. 32, 2603-2616.
30. Pallos J., Bodai L., Lukacsovich T., Purcell J. M., Steffan J. S., Thompson L. M., and, Marsh J. L., (2008) Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 17, 3767-3775.
31. Perego C., Fumagalli S., and, De Simoni M. G., (2011) Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice. J. Neuroinflammation 8, 174.
32. Qiu X., Brown K. V., Moran Y., and, Chen D., (2010) Sirtuin regulation in calorie restriction. Biochim. Biophys. Acta 1804, 1576-1583.
33. Rao K. V., Reddy P. V., Curtis K. M., and, Norenberg M. D., (2011) Aquaporin-4 expression in cultured astrocytes after fluid percussion injury. J. Neurotrauma 28, 371-381.
34. Rhee J. W., Lee K. W., Kim D., Lee Y., Jeon O. H., Kwon H. J., and, Kim D. S., (2007) NF-kappaB-dependent regulation of matrix metalloproteinase-9 gene expression by lipopolysaccharide in a macrophage cell line RAW 264.7. J. Biochem. Mol. Biol. 40, 88-94.
35. Rothgiesser K. M., Erener S., Waibel S., Luscher B., and, Hottiger M. O., (2010) SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. J. Cell Sci. 123, 4251-4258.
36. Taylor D. M., Balabadra U., Xiang Z., et al,. (2011) A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem. Biol. 6, 540-546.
37. Town T., Nikolic V., and, Tan J., (2005) The microglial "activation" continuum: from innate to adaptive responses. J. Neuroinflam-mation 2, 24.
38. Wang F., Nguyen M., Qin F. X., and, Tong Q., (2007) SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 6, 505-514.
39. Wang Y. P., Zhou L. S., Zhao Y. Z., et al,. (2014) Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress. EMBO J. 33, 1304-1320.
40. Zhao Y., Luo P., Guo Q., et al,. (2012) Interactions between SIRT1 and MAPK/ERK regulate neuronal apoptosis induced by traumatic brain injury in vitro and in vivo. Exp. Neurol. 237, 489-498.